<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797104</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-004</org_study_id>
    <nct_id>NCT04797104</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction</brief_title>
  <acronym>LIBerate-FH</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with&#xD;
      monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to&#xD;
      placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C&#xD;
      lowering drug therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled, Phase 3 study of 24 weeks duration.&#xD;
      Approximately 600 males and females aged ≥18 years with clinical or genetic heterozygous FH&#xD;
      who fulfill the inclusion and exclusion criteria will be enrolled. Patients will be&#xD;
      randomized in a 2:1 ratio to LIB003 (400 patients) or placebo (200 patients) administered SC&#xD;
      Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The&#xD;
      total study duration will be up to 35 weeks which includes up to an 11-week Screening Period&#xD;
      (which may include up to a 8-week washout) and 24 weeks of study drug treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blind placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind to treatment (LIB003 or placebo) and lipid data</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline compared to placebo in LDL-C level</measure>
    <time_frame>24 weeks</time_frame>
    <description>LS mean percent change in LDL-cholesterol compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAE) as assessed by Medical Dictionary for Regulatory Activities as mild, moderate or severe compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum free PCSK9 with LIB003 compared to placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in percent LS mean between LIB003 and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Heterozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg (1.2 mL) SC Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.2 mL SC Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lerodalcibep</intervention_name>
    <description>300 mg Q4W</description>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>LIB003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written and signed informed consent prior to any study-specific&#xD;
             procedure;&#xD;
&#xD;
          -  Weight of ≥40 kg (88 lbs) and body mass index (BMI) ≥17 and ≤42 kg/m2;&#xD;
&#xD;
          -  Diagnosis of definite, probable or possible HeFH based either on clinical criteria&#xD;
             (Simon Broome register criteria or Dutch Lipid Clinics [DLC] Network Criteria) or&#xD;
             genotyping and at the defined eligibility visit (screening or post&#xD;
             washout/stabilization)&#xD;
&#xD;
          -  LDL-C ≥70 mg/dL (if very-high risk for CVD) or ≥100 mg/dL (if high risk for CVD) and&#xD;
             TG ≤400 mg/dL while on stable lipid lowering oral drug therapy (eg, maximally&#xD;
             tolerated statin with or without ezetimibe); Patients unable to tolerate approved&#xD;
             doses of a statin may take lower than approved doses and less frequently than daily as&#xD;
             long as the dose and dosing frequency is consistent.&#xD;
&#xD;
          -  Patients with documentation of inability to tolerate any statin at any dose, or&#xD;
             history of rhabdomyolysis, and unable to tolerate any other allowed oral lipid&#xD;
             lowering agent, and thus on no lipid lowering therapy must have an LDL-C ≥190 mg/dL&#xD;
             (4.9 mmol/L) at the Screening Visit unless they have a documented pathogenic FH&#xD;
             variant;&#xD;
&#xD;
          -  Stable diet and other lipid lowering oral therapies besides statins and ezetimibe&#xD;
             including bile-acid sequestrants, OM-3 compounds, fenofibrate, bezafibrate, nicotinic&#xD;
             acid and bempedoic acid or combinations thereof for at least 4 weeks&#xD;
&#xD;
          -  Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a&#xD;
             washout period of ≥4 weeks after the last dose; for those on a dose of 300 mg or 420&#xD;
             mg Q4W (≤31 days) the washout period is ≥8 weeks following last dose;&#xD;
&#xD;
          -  Females of childbearing potential must be using a highly effective form of&#xD;
             contraception if sexually active and have negative urine pregnancy test at the last&#xD;
             Screening Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of prohibited oral lipid lowering agents mipomersen or lomitapide within 6 months&#xD;
             of screening, gemfibrozil within 6 weeks of the Screening Visit or LDL/plasma&#xD;
             apheresis within 2 months prior to Day 1;&#xD;
&#xD;
          -  Documented history of HoFH defined clinically or genetically&#xD;
&#xD;
          -  History of any prior or active clinical condition or acute and/or unstable systemic&#xD;
             disease compromising patient inclusion, at the discretion of the Investigator.&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active, not using or unwilling to&#xD;
             use a highly effective form of contraception, pregnant or breastfeeding, or who have a&#xD;
             positive urine pregnancy test at the last Screening Visit;&#xD;
&#xD;
          -  Moderate to severe renal dysfunction, defined as an eGFR &lt;30 mL/min/1.73m2&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction, history of liver transplant, and/or AST&#xD;
             or ALT &gt;2.5 × the ULN&#xD;
&#xD;
          -  Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by TSH &lt;LLN&#xD;
             or &gt;1.5 × ULN, respectively,&#xD;
&#xD;
          -  Uncontrolled Type 1 or Type 2 DM (fasting glucose≥200 mg/dL or HbA1c of ≥9%;&#xD;
&#xD;
          -  Planned cardiac surgery or revascularization;&#xD;
&#xD;
          -  New York Heart Association III-IV heart failure&#xD;
&#xD;
          -  Previous treatment with LIB003 or any adnectin product;&#xD;
&#xD;
          -  Any other finding which, in the opinion of the Investigator, would compromise the&#xD;
             patient's safety or participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kallend, MB BCh</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>12000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital,</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Clinic, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0586</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carbohydrate and Lipid Metabolism Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Lipidology, Department of Medicine University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical School</name>
      <address>
        <city>İzmir</city>
        <state>Bornova</state>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lerodalcibep</keyword>
  <keyword>PCSK9 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

